Abstract
Targeted mRNA degradation by short interfering RNAs (siRNAs) offers a great potential to treat cancers. siRNA therapeutics for leukemias are, however, hindered by poor intracellular uptake, limited blood stability and nonspecific delivery. To solve these problems, we developed an anti-JL1 immunonanoplex (antibody-coupled nanocomplex) for siRNA delivery using anti-JL1 minibody (leukemia cell-specific minibody) conjugated to oligo-9-Arg peptide (9R) for effective siRNA delivery to leukemic cells. The anti-JL1 immunonanoplexes were able to deliver siRNA specifically to leukemic cells (CEM and Jurkat), but not to control cancer cells (H9). According to FACS and confocal microscopic analysis, siRNAs delivered by immunonanoplex particles were rapidly taken up by the JL1-positive cancer cells in 2 h. Furthermore, we showed that the anti-JL1 immunonanoplexes were effectively targeted to JL1-positive cells (CEM) inoculated in the mouse bone marrow. These results suggest that the anti-JL1 immunonanoplex is a powerful siRNA delivery system for human leukemia therapies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akhtar, S., and Benter, I.F. (2007). Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 117, 3623–3632.
Chiu, Y.L., Ali, A., Chu, C.Y., Cao, H., and Rana, T.M. (2004). Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem. Biol. 11, 1165–1175.
Crombez, L., Charnet, A., Morris, M.C. (2007). Aldrian-Herrada, G., Heitz, F., and Divita, G. A non-covalent peptide-based strategy for siRNA delivery. Biochem. Soc. Trans. 35, 44–46.
Ei-Andaloussi, S., Holm, T., and Langel, U. (2005). Cell penetrating peptides: mechanisms and applications. Curr. Pharm. Des. 11, 3597–3611.
Elmén, J., Thonberg, H., Ljungberg, K., Frieden, M., Westergaard, M., Xu, Y., Wahren, B., Liang, Z., Ørum, H., Koch, T., et al. (2005). Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 33, 439–447.
Goffinet, C., and Keppler, O.T. (2006). Efficient nonviral gene delivery into primary lymphocytes from rats and mice. FASEB J. 20, 500–502.
Guo, S., Tschammer, N., Mohammed, S., and Guo, P. (2005). Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechaninsm of phi 29 motor pRNA. Hum. Gene Ther. 16, 1097–1109.
Kim, T.J., and Park, S.H. (1998). Immunotherapeutic potential of JL1, a thymocyte surface protein, for leukemia. J. Korean Med. Sci. 13, 455–458.
Kumar, P., Wu, H., McBride, J.L., Jung, K.E., Kim, M.H., Davidson, B.L., Lee, S.K., Shankar, P., and Manjunath, N. (2007). Transvascular delivery of small interfering RNA to the central nervous system. Nature 448, 39–43.
Kumar, P., Ban, H.S., Kim, S.S., Wu, H., Pearson, T., Greiner, D.L., Laouar, A., Yao, J., Haridas, V., Habiro, K., et al. (2008). T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134, 577–586.
Kushida, T., Inaba, M., Hisha, H., Ichioka, N., Esumi, T., Ogawa, R., Iida, H., and Ikehara, H. (2001). Intra-bone marrow injection of allogeneic bone marrow cells: a powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice. Blood 97, 3292–3299.
Liu, B. (2007). Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA. Brief. Funct. Genomic. Proteomic. 6, 112–119.
Morris, M.C., Depollier, J., Mery, J., Heitz, F., and Divita, G. (2001). A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol. 19, 1173–1176.
Morrissey, D.V., Lockridge, J.A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23, 1002–1007.
Novina, C.D., and Sharp, P.A. (2004). The RNAi revolution. Nature 430, 161–164.
Park, S.H., Bae, Y.M., Kwon, H.J., Kim, T.J, Kim, J., Lee, S.J., and Lee, S.K. (1993). JL1, a novel differentiation antigen of human cortical thymocyte. J. Exp. Med. 178, 1447–1451.
Park, W.S., Bae, Y.M., Chung, D.H., Kim, T.J., Choi, E.Y., Chung, J.K., Lee, M.C., Park, S.Y., Park, M.H., and Park, S.H. (1998). A cell surface molecule, JL1; a specific target for diagnosis and treatment of leukemias. Leukemia 12, 1583–1590.
Pirollo, K.F., and Chang, E.H. (2008). Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res. 68, 1247–1250.
Pirollo, K.F., Zon, G., Rait, A., Zhou, Q., Yu, W., Hogrefe, R., and Chang, E.H. (2006). Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum. Gene Ther. 17, 117–124.
Schiffelers, R.M., Ansari, A., Xu, J., Zhou, Q., Tang, Q., Storm, G., Molema, G., Lu, P.Y. Scaria, P.V., and Woodle, M.C. (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, e149.
Shin, Y.K., Choi, E.Y., Kim, S.H., Chung, J., Chung, D.H., Park, W.S., Jung, K.C., Kim, H.S., Park, S., Kim, H.J., et. al. (2001). Expression of leukemia-associated antigen, JL1, in bone marrow and thymus. Am. J. Pathol. 158, 1473–1480.
Shin, Y.K., Choi, Y.L., Choi, E.Y., Kim, M.K., Kook, M.C., Chung, J., Choi, Y.K., Kim, H.S., Song, H.G., and Park, S.H. (2003). Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications. Cancer Immunol. Immunother. 52, 506–512.
Song, E., Lee, S.K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., and Lieberman, J. (2003). RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9, 347–351.
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173–1788.
Swami, A., Kurupati, R.K., Pathak, A., Singh, Y., Kumar, P., and Gupta, K.C. (2007). A unique and highly efficient non-viral DNA/siRNA delivery system based on PEI-bisepoxide nanoparticles. Biochem. Biophysic. Res. Commun. 362, 835–841.
Urban-Klein, B., Werth, S., Abuharbeid, S., Czubayko, F., and Aigner, A. (2005). RNAi-mediated gene-targeting through systemic application of polyethlenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12, 461–466.
Vornlocher, H.P. (2006). Antibody-directed cell-type-specific delivery of siRNA. Trends Mol. Med. 12, 1–3.
Williams, B.R. (2005). Targeting specific cell types with silencing RNA. N. Engl. J. Med. 353, 1410–1411.
Zhou, D., Zhang, J., Wang, C., Bliesath, J.R., He, Q., Yu, D., Li-He, Z., and Wong-Staal, F. (2009). A method for detecting and preventing negative RNA interference in preparation of lentiviral vectors for siRNA delivery. RNA 15, 732–740.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Lee, Y.K., Kim, K.S., Kim, J.S. et al. Leukemia-specific siRNA delivery by immunonanoplexes consisting of anti-JL1 minibody conjugated to oligo-9 Arg-peptides. Mol Cells 29, 457–462 (2010). https://doi.org/10.1007/s10059-010-0056-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10059-010-0056-5